Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664263 | 1.00 | CREBBP (0.42) | CREBBPDYRK1AACVR1PIM1KDM5B | |
| SCHEMBL20122990 | 0.89 | CREBBP (0.42) | CREBBPDYRK1AACVR1PIM1KDM5B | |
| SCHEMBL30664190 | 0.89 | CREBBP (0.42) | CREBBPDYRK1AACVR1PIM1KDM5B | |
| SCHEMBL20122925 | 0.89 | DYRK1B (0.46) | CREBBPDYRK1ADYRK1B | |
| SCHEMBL30664251 | 0.89 | DYRK1B (0.46) | CREBBPDYRK1ADYRK1B | |
| SCHEMBL20122718 | 0.87 | BRD4 (0.34) | CREBBPDYRK1AACVR1DYRK1BKCNH2 | |
| SCHEMBL20122709 | 0.85 | L3MBTL1 (0.40) | CREBBPDYRK1AKDM5BDYRK1BGABRA1 | |
| SCHEMBL29756293 | 0.85 | L3MBTL1 (0.40) | CREBBPDYRK1AKDM5BDYRK1BGABRA1 | |
| SCHEMBL20123032 | 0.81 | DYRK1A (0.41) | DYRK1AMAOA | |
| SCHEMBL29756325 | 0.81 | DYRK1A (0.41) | DYRK1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | CREBBP 1593/4885DYRK1A 493/4885ACVR1 30/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | CREBBP 1593/4885DYRK1A 493/4885ACVR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.